Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

• DOI: 10.18632/oncotarget.21602
• Publication Date: 2017-10-08T07:02:27Z
• Authors: Yuko Oya; Tatsuya Yoshida; Hiroaki Kuroda; Masashi Mikubo; Chiaki Kondo; Junichi Shimizu; Yoshitsugu Horio; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe
• Keywords: Clinical Oncology

Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported many studies. However, clinical parameters remains unclear advanced NSCLC patients.Among 124 patients, 108 (88%) were performance status (PS) 0 to 1. PD-L1 was assessed 89 51 (57%) having positive expression. In all objective response rate (ORR) elevated CRP levels (≥ 1 mg/dl) significantly worse than those without (< (8.3 vs 23.4%, p = 0.0180). The PS 2), smoking index 400), LDH 245 IU/L) associated shorter PFS OS nivolumab. Multivariate analyses showed that significant factors longer nivolumab.We retrospectively analyzed who received as subsequent treatment. patient characteristics, laboratory data at baseline (C-reactive protein [CRP] lactate dehydrogenase [LDH]), expression, response, progression-free (PFS), overall (OS) evaluated.Clinical parameters, such PS, serum CRP, LDH, status, duration